A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis (NCT07217015)
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study With an Open-label Period Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
🩺 Plain-English Summary (8th-Grade Level)
This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity and extent of AD, the safety and tolerability of KT-621, how KT-621 behaves in the body, and how the body responds to KT-621. This is a 16-week double-blind, placebo-controlled study with a 52-week open-label period.
Who can join: Review the eligibility criteria below.
Location: Kymera Investigative Site — Birmingham, Alabama
Age range: 12 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (68 Sites)
Showing the first 25 of 68 sites.
- Kymera Investigative Site — Birmingham, Alabama
- Kymera Investigative Site — North Little Rock, Arkansas
- Kymera Investigative Site — Freemont, California
- Kymera Investigative Site — Los Angeles, California
- Kymera Investigative Site — Los Angeles, California
- Kymera Investigative Site — Santa Monica, California
- Kymera Investigative Site — Delray Beach, Florida
- Kymera Investigative Site — Jacksonville, Florida
- Kymera Investigative Site — Miami, Florida
- Kymera Investigative Site — Miramar, Florida
- Kymera Investigative Site — Normal, Illinois
- Kymera Investigative Site — Indianapolis, Indiana
- Kymera Investigative Site — Ann Arbor, Michigan
- Kymera Investigative Site — Detroit, Michigan
- Kymera Investigative Site — The Bronx, New York
- Kymera Investigative Site — Fargo, North Dakota
- Kymera Investigative Site — Portland, Oregon
- Kymera Investigative Site — Portland, Oregon
- Kymera Investigative Site — Philadelphia, Pennsylvania
- Kymera Investigative Site — San Antonio, Texas
- Kymera Investigative Site — San Antonio, Texas
- Kymera Investigative Site — Darlinghurst, New South Wales
- Kymera Investigative Site — Kogarah, New South Wales
- Kymera Investigative Site — Brisbane, Queensland
- Kymera Investigative Site — Woolloongabba, Queensland
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
- ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
- A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
- Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
- A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California
Explore by condition: All Atopic Dermatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.